**Streptococcus pyogenes** Pneumonia in Adults: Clinical Presentation and Molecular Characterization of Isolates 2006-2015

Esther Tamayo¹, Milagrosa Montes¹,², Diego Vicente¹,², Emilio Pérez-Trallero¹,²,³ *

¹ Biomedical Research Center Network for Respiratory Diseases (CIBERES), San Sebastián, Spain,  
² Microbiology Department, Hospital Universitario Donostia-Instituto Biodonostia, San Sebastián, Spain,  
³ Medicine Faculty, University of the Basque Country, UPV/EHU, San Sebastián, Spain

* mikrobiol@terra.com

**Abstract**

**Introduction**

In the preantibiotic era **Streptococcus pyogenes** was a common cause of severe pneumonia but currently, except for postinfluenza complications, it is not considered a common cause of community-acquired pneumonia in adults.

**Aim and Material and Methods**

This study aimed to identify current clinical episodes of **S. pyogenes** pneumonia, its relationship with influenza virus circulation and the genotypes of the involved isolates during a decade in a Southern European region (Gipuzkoa, northern Spain). Molecular analysis of isolates included **emm**, multilocus-sequence typing, and superantigen profile determination.

**Results**

Forty episodes were detected (annual incidence 1.1 x 100,000 inhabitants, range 0.29–2.29). Thirty-seven episodes were community-acquired, 21 involved an invasive infection and 10 developed STSS. The associated mortality rate was 20%, with half of the patients dying within 24 hours after admission. Influenza coinfection was confirmed in four patients and suspected in another. The 52.5% of episodes occurred outside the influenza seasonal epidemic. The 67.5% of affected persons were elderly individuals and adults with severe comorbidities, although 13 patients had no comorbidities, 2 of them had a fatal outcome. Eleven clones were identified, the most prevalent being **emm1/ST28** (43.6%) causing the most severe cases.

**Conclusions**

**S. pyogenes** pneumonia had a continuous presence frequently unrelated to influenza infection, being rapidly fatal even in previously healthy individuals.
Introduction

The global burden of *Streptococcus pyogenes* disease is high, causing a wide range of mild to severe clinical manifestations that comprise an important cause of morbidity and mortality worldwide. In high income countries, the way that the disease manifests itself has changed during the last few decades. During the mid-20th century, *S. pyogenes* was a common cause of epidemic outbreaks and community-acquired pneumonia (CAP) [1–3]. Currently *S. pyogenes* is considered a rare cause of community acquired pneumonia, being a clinical entity seen only sporadically after an influenza infection [4–5]. However, the involvement of *S. pyogenes* in lower respiratory tract infections is not infrequently seen during the course of invasive infections, which is associated with an exceptionally high mortality rate [6]. Despite of the severity of the illness, few studies have been designed to comprehensively describe large *S. pyogenes* pneumonia case series [7,8], with most recent publications being case reports [9–11]. Although some molecular and epidemiological data regarding *S. pyogenes* pneumonic episodes can be extracted from studies reporting invasive *S. pyogenes* disease, they are not focused on pneumonia and precise data are scarce. The aims of the present study were to describe the clinical features, prognosis and relation with influenza infection of *S. pyogenes* pneumonia over a decade and to determine the molecular characteristics (*emm*-type, sequence type, antimicrobial resistance determinants, and superantigen profile) of involved isolates.

Materials and Methods

Study area and sample

The study was conducted at Hospital Universitario Donostia, which is the referral hospital of the province of Gipuzkoa, northern Spain, and attends a population of about 350,000 adults >18 years old (annual range 348,726 to 354,475 inhabitants), with an annual mean of 50,640 adult admissions. Medical charts of adult patients with a diagnosis of invasive *S. pyogenes* infection or with a *S. pyogenes* isolate obtained from lower respiratory tract specimen between January 2006 and December 2015 were revised.

Definition of *S. pyogenes* pneumonia was based on the presence of clinical findings (cough, fever, sputum production, and pleuritic chest pain), demonstrable infiltrate on chest radiograph or other imaging techniques and a positive *S. pyogenes* culture obtained from blood, pleural fluid, or bronchial secretions (bronchoalveolar lavage, bronchial aspirate, or sputum). Bronchial secretions yielding *S. pyogenes* positive cultures were included in the study when it appeared as a single or predominant pathogen. In addition, sputum samples needed to demonstrate >25 leukocytes and <10 squamous epithelial cells per low power field on direct Gram-stain.

Pneumonia was considered invasive when *S. pyogenes* was isolated from a sterile site, or when obtained from a non-sterile lower respiratory tract site but the clinical presentation and analytical data (Streptococcal Toxic Shock Syndrome (STSS), elevated procalcitonin level, etc.) were consistent with invasive disease.

Isolates were confirmed as *S. pyogenes* by routine identification (colony morphology, beta-hemolysis on blood agar plates, agglutination with specific antisera [SlideX, Streptokit; bioMérieux, Marcy l’Etoile, France]), and MALDI-TOF (Matrix Assisted Laser Desorption Ionization-Time of Flight, mass spectrometry analysis Biotype 3.0, Bruker Daltonics Inc. Billerica, MA, USA).

To relate the streptococcal pneumonic cases with the influenza virus circulation, the influenza rate (epidemic threshold ≥ 80 cases per 100,000 inhabitants) during the previous weeks and coinciding with each *S. pyogenes* pneumonia case were recorded (Red Nacional de Vigilancia Epidemiológica. Sistema de Vigilancia de la Gripe en España. ISCIII [http://vgripe.isciii.es/](http://vgripe.isciii.es/))
In patients diagnosed with pneumonia and suspicion of flu during the seasonal influenza period, PCR influenza tests (AH1, AH3 and B) were performed. Demographic and clinical variables were obtained from the patient’s medical charts. Only heavy smokers, those smoking > 20 cigarettes per day, were included among smokers. The Pneumonia Severity Index developed by Fine et al [12] was assigned in each patient. Mortality within 30 days was recorded.

Antimicrobial susceptibility testing
Minimum inhibitory concentrations (MICs) were determined by the broth microdilution method using Sensititre Microtiter Trays (Trek Diagnostics Systems, East Sussex, UK) and cation-adjusted Mueller-Hinton II broth (bioMérieux, Marcy l’Étoile, France) supplemented with 3–5% v/v lysed horse blood. Interpretation was performed according to the Clinical and Laboratory Standards Institute guidelines [13].

Molecular characterization of isolates
All isolates were characterized by sequencing the 180nt of the 5’ variable region of the emm gene (http://www.cdc.gov/streplab/protocol-emm-type.html) and by multilocus sequence typing (http://pubmlst.org/spyogenes/). In isolates showing erythromycin resistance, detection of the macrolide resistance genes erm(B), erm(A)TR and mef was performed as previously described [14]. In isolates with reduced susceptibility to fluoroquinolones (ciprofloxacin MIC ≥2 mg/L) the parC and gyrA genes were sequenced [15]. Clone was defined by the combination of the emm-type, sequence type (ST) and antimicrobial susceptibility pattern.

Detection of ssa, speA, speC and smeZ superantigen genes was performed in two multiplex PCR-s using the chromosomally encoded virulence factor genes speB and slo as successful reaction controls as previously described [16].

Ethics
The study was an observational, laboratory-based, surveillance study with review of medical records. The patient information was anonymized and study investigators and research associates had no direct patient contact and the study protocol involved no change in patient care or management; all decisions regarding patient investigation and treatment were at the discretion of the attending physician. The institutional ethics committee (Ethics Committee for Clinical Research of the Health Area of Gipuzkoa), specifically approved this study.

Statistical Analysis
The associations of the variables of sex, emm-type, STSS, predisposing conditions, bilobar or multilobar pneumonia, season, and patient evolution (death or survival) were calculated by Fisher’s exact probability test. To analyze the independent effect of each variable in relation to patient outcome, we performed a logistic regression analysis including death and variables with an initial P value of ≤ 0.2 tested in the bivariate analysis. Data were analyzed with the IBM SPSS Statistics, Software version 22.

Results
Incidence
From January 2006 to December 2015, 40 S. pyogenes pneumonia episodes were detected. The number per annual period ranged from 1 to 8 episodes, without any significant trend during the study period (annual average incidence 1.14 episodes per 100,000 inhabitants, range 0.29–2.29).
Most cases occurred in winter (n = 26, 65%) and spring (n = 10, 25%). Nineteen cases (47.5%) occurred when the influenza virus circulation reached the epidemic threshold (Table 1) but only five cases (four confirmed and one suspected) had relation with previous or concomitant influenza infection. There were 8 patients whose pneumonia was diagnosed during a flu period in which a PCR influenza test result was not available. Only one of these 8 patients was suspected of having flu, although in this patient the test was not performed or not recorded.

All but two cases included in the study were hospitalized. The age of patients ranged from 25 to 90 years with a median of 58.4 years and a mean of 60 years. Overall, 32.5% of cases occurred in patients older than 64 years (incidence 1.48 x100,000 elderly people). Nearly two-thirds (n = 25, 62.5%) of the patients were male.

All but 3 cases (1 nosocomial and 2 in nursing home residences) were community-acquired. The nosocomial pneumonia in a 66-year-old patient with a kidney transplant and multiple comorbidities, who died 20 days after admission, had abundant growth of *S. pyogenes* and *Pseudomonas aeruginosa* in bronchial secretions. This patient had also a cytomegalovirus infection.

Overall, in 20% of cases coinfections were detected, although viral coinfection was not investigated in some cases (Table 1). In addition to the patient coinfected with *P. aeruginosa* and cytomegalovirus, another 7 coinfections were: 2 with H3N2 Influenza A virus, 1 with H1N1pdm09 influenza A virus, 1 with influenza B virus, 2 with non-encapsulated *Haemophilus influenzae*, and 1 with *Staphylococcus aureus*.

**Clinical findings**

In 21 patients (52.5%), *S. pyogenes* pneumonia presented as an invasive infection. In 17 of them, *S. pyogenes* was obtained from blood and in 1 from pleural fluid. The remaining 3 episodes were considered invasive infections even though the microorganism was only isolated in low respiratory secretions, as all had severe sepsis with renal failure, metabolic acidosis, hemodynamic instability, and elevated procalcitonin and C-reactive protein levels. Two of them developed STSS and died.

Twenty-seven patients had severe disease (Fine IV or V). Ten patients developed STSS. In 15 patients, pneumonia was multilobar. In 33 episodes (82.5%), the lower lobes were affected, 11 patients presented with pleural effusion, and cavitation was evidenced in 4 (Table 1).

**Comorbidities and predisposing factors**

Notable underlying medical conditions were the presence of hypertension (37.5%), chronic obstructive pulmonary disease (COPD) (20%), and diabetes (20%) (Table 1). No comorbidities were detected in 13 patients (32.5%), although a woman without comorbidities was 35 weeks pregnant.

Various antibiotic regimens were used, the most commonly prescribed being a combination of a beta-lactam with clindamycin (n = 11) or with levofloxacin (n = 10), monotherapy with a beta-lactam (n = 10), monotherapy with levofloxacin (n = 7) or a combination of a beta-lactam with clindamycin and levofloxacin (n = 2). No relationship between the treatment received and mortality or clinical course was found.

**Mortality (case fatality)**

The overall 30-day case fatality was 20% (8/40), which increased to 30.8% (4/13) in patients older than 64 years. Half of the patients with a fatal outcome (4/8), died within 24 hours after
Table 1. Description of the 40 *Streptococcus pyogenes* pneumonia episodes in adults and molecular characteristics of involved isolates. Gipuzkoa, Spain, 2006–2015.

| Date (mo/ y) | Age (y) | Sex | Comorbidities and predisposing factors | STSS | Invasive | Affected lung area | Fine | 30-d mortality (days to death) | Biweekly influenza threshold (per 100,000) | Coinfection | Isolation site | *emm* | ST | Exotoxins genes |
|--------------|--------|-----|----------------------------------------|------|----------|---------------------|------|---------------------------------|-----------------------------------------------|-------------|----------------|-------|-----|-----------------|
| 1/2006       | 61     | Male | IST                                    | *   | Yes      | RUL (cavitary lesions) | V    | < 80                            | -                              | -           | Blood         | 1.0  | 28 | slo, speB, speC, smeZ |
| 04/2006      | 80     | Male | COPD, AHT, RF, atrial fibrillation      | -   | -        | RUL                  | IV   | < 80                            | Staphylococcus aureus            | BS          |               |       |     |                 |
| 02/2007      | 55     | Female | -                                      | -   | -        | RLL+ RUL            | II   | 355                            | Viral study not performed        | BS          | 6.4  | 382 | slo, speB, speC |
| 05/2007      | 59     | Male | COPD, AHT, DM                          | -   | -        | RLL                  | II   | < 80                            | -                              | BS          | 6.0  | 382 | slo, speB, speC |
| 01/2008      | 63     | Male | COPD, DM                               | -   | -        | RLL+ LLL            | IV   | 296                            | Viral study not performed        | BS          | 1.0  | 28 | slo, speA, speB, smeZ |
| 02/2008      | 44     | Male | -                                      | Yes | Yes      | RLL+ LLL pleural effusion | V    | 265                            | Viral study not performed        | Blood + BS | 1.0  | 28 | slo, speA, speB, smeZ |
| 02/2008      | 44     | Female | -                                      | Yes | Yes      | LLL + pleural effusion | V    | 168                            | Viral study not performed        | Blood + BS | 5.46 | 99 | slo, speB, speC |
| 02/2008      | 46     | Male | Smoker, AHT, alcohol abuse             | -   | Yes      | RUL                  | III  | 127                            | Viral study not performed        | Blood + BS | 1.0  | 28 | slo, speA, speB, smeZ |
| 04/2008      | 44     | Male | Cerebral palsy (nursing home)          | -   | -        | LLL                  | III  | < 80                            | -                              | BS          | 6.0  | 382 | slo, speB, speC |
| 06/2008      | 45     | Male | Smoker, alcohol abuse                  | -   | Yes      | RLL+ LLL pleural effusion | V    | < 80                            | -                              | Blood       | 1.0  | 28 | slo, speB, speB, smeZ |
| 07/2008      | 72     | Male | COPD, DM, AHT, atrial fibrillation, stroke | -   | Yes      | RLL                  | V    | < 80                            | -                              | Blood + BS | 87   | 62 | slo, speB, speC, smeZ, ssa |
| 10/2008      | 63     | Female | AHT                                    | -   | -        | LLL                  | ND   | < 80                            | -                              | BS          | 4.0  | 39 | slo, speB, speC, smeZ, ssa |
| 05/2009      | 41     | Male | -                                      | -   | -        | RUL                  | I    | < 80                            | -                              | BS          | 3.1  | 15 | slo, speA, speB, ssa |
| 06/2010      | 64     | Male | COPD                                   | -   | -        | RLL                  | IV   | < 80                            | -                              | BS          | 12.0 | 36 | slo, speB |
| 04/2011      | 66     | Male | AHT, IST, RF, HD (nosocomial)          | -   | -        | RUL+RML + RLL + LLL | IV   | Death (20 d) | Pseudomonas aeruginosa | BS          | 81   | 624 | slo, speB |
| 12/2011      | 63     | Male | -                                      | -   | -        | RLL                  | I    | < 80                            | Haemophilus influenzae           | BS          | 6.0  | 382 | slo, speB, speC |
| 02/2012      | 78     | Male | AHT, HD, atrial fibrillation           | -   | -        | RLL+ LLL            | IV   | 327                            | Viral study not performed        | BS          | 1.0  | 28 | slo, speA, speB, smeZ |

(Continued)
| Date (mo/ y) | Age (y) | Sex | Comorbidities and predisposing factors | STSS | Invasive | Affected lung area | Fine | 30-d mortality (days to death) | Biweekly influenza threshold (per 100,000) | Coinfection | Isolation site | emm | ST | Exotoxins genes |
|-------------|---------|-----|--------------------------------------|------|----------|-------------------|------|-------------------------------|---------------------------------------------|-------------|----------------|-----|-----|----------------|
| 02/ 2012    | 39      | Female | -                                    | Yes  | Yes      | RLL+LLL           | V    | Death (<24 h)                 | 229                                                      | -           | Blood + BS     | 1.0 | 28 | slo, speA, speB, smeZ |
| 03/ 2012    | 54      | Female | -                                    | -    | Yes      | RLL               | I    | < 80                          | -                                                          | Blood       | 1.0 | 28 | slo, speA, speB, smeZ |
| 03/ 2012    | 67      | Female | AHT, DM, IST, neoplastic disease     | -    | -        | RUL (cavitary lesions) | V    | < 80                          | -                                                          | BS          | 1.0 | 28 | slo, speA, speB, smeZ |
| 03/ 2012    | 90      | Male   | COPD, RF                             | Yes  | Yes      | RLL               | V    | Death (<24 h)                 | < 80                                                      | -           | BS          | 6.0 | 382 | slo, speB, speC |
| 04/ 2012    | 46      | Male   | Smoker, alcohol abuse                | Yes  | Yes      | RLL+LLL+pleural effusion | V    | < 80                          | -                                                          | Blood       | 1.0 | 28 | slo, speA, speB, smeZ |
| 11/ 2012    | 87      | Male   | AHT, DM                              | -    | -        | RUL+LLL+pleural effusion | V    | < 80                          | -                                                          | BS          | 75.0 | 150 | slo, speB, speC |
| 03/ 2013    | 70      | Female | IST                                  | Yes  | Yes      | RLL+ RUL          | V    | Death (<24 h)                 | 144                                                      | Influenza B | Blood + BS | 1.0 | 28 | slo, speA, speB, smeZ |
| 08/ 2013    | 64      | Female | AHT                                  | -    | -        | LLL               | III  | < 80                          | Haemophilus influenzae                                  | BS          | 75.0 | 150 | slo, speB, speC |
| 12/ 2013    | 74      | Male   | Smoker, AHT, HD,RF (nursing home)    | -    | Yes      | RLL+pleural effusion | V    | 181                           | -                                                          | Blood       | 89.0 | 101 | slo, speB    |
| 01/ 2014    | 59      | Male   | AHT                                  | Yes  | Yes      | RLL               | V    | Death (3 d)                   | 249                                                      | -           | Blood       | 3.1 | 315 | slo, speA, speB, ssa |
| 01/ 2014    | 47      | Male   | AHT, Morbid obesity                  | -    | Yes      | LLL+RML+RLL+pleural effusion | IV   | -                             | 249                                                      | Influenza H1N1pdm09 | Blood + BS | 1.0 | 28 | slo, speA, speB, smeZ |
| 01/ 2014    | 74      | Male   | AHT, DM                              | -    | -        | RUL+ RML          | V    | -                             | 296                                                      | -           | BS          | 3.1 | 15 | slo, speA, speB, ssa |
| 02/ 2014    | 86      | Female | COPD, AHT, DM                       | -    | Yes      | RLL+LLL           | IV   | Death (7 d)                   | < 80                                                      | -           | Blood       | 1.0 | 28 | slo, speA, speB, smeZ |
| 03/ 2014    | 77      | Male   | COPD, DM, HD                         | -    | Yes      | LLL               | V    | < 80                          | -                                                          | BS          | 3.1 | 315 | slo, speA, speB, ssa |
| 03/ 2014    | 38      | Female | -                                    | Yes  | Yes      | LLL               | V    | Death (3 d)                   | < 80                                                      | -           | BS          | 1.0 | 28 | slo, speA, speB, smeZ |
| 01/ 2015    | 25      | Female | -                                    | Yes  | Yes      | RLL + LLL +pleural effusion | IV   | -                             | 318                                                      | -           | Blood + BS | 1.0 | 28 | slo, speB, smeZ |
| 01/ 2015    | 73      | Male   | IST                                  | -    | -        | RLL+pleural effusion (cavitary lesions) | IV   | -                             | 318                                                      | Influenza A H3 | BS          | 3.1 | 15 | slo, speA, speB, ssa |

(Continued)
| Date (mo/ y) | Age (y) | Sex | Comorbidities and predisposing factors | STSS | Invasive | Affected lung area | Fine | 30-d mortality (days to death) | Biweekly influenza threshold (per 100,000) | Coinfection | Isolation site | emm | ST | Exotoxins genes |
|------------|--------|-----|--------------------------------------|------|----------|-------------------|------|-----------------------------|------------------------------------------|-------------|----------------|-----|-----|----------------|
| 02/ 2015   | 37     | Female | Pregnant                           | -    | Yes      | LLL + pleural effusion | III | -                          | 484                                      | Influenza A H3 | Blood                     | 3.39 | 315 | slo, speA, speB, ssa |
| 02/ 2015   | 32     | Female | -                                   | -    | -        | RUL + LUL (cavitary lesions) | I    | -                          | 292                                      | -            | BS                              | 1.0  | 28  | slo, speB, smeZ  |
| 02/ 2015   | 49     | Male   | Smoker                              | -    | -        | LLL                             | II   | -                          | 215                                      | Influenza suspected. Viral study not performed | BS              | 89.0 | 101 | slo, speB, speC  |
| 03/ 2015   | 44     | Male   | -                                   | -    | -        | LLL                             | I    | -                          | 172                                      | -            | BS                              | 1.0  | 28  | slo, speA, speB, smeZ |
| 03/ 2015   | 50     | Female | Yes                                 | Yes  | -        | RLL + pleural effusion          | IV   | -                          | 122                                      | Viral study not performed | Pleural fluid | 77.0 | 63  | slo, speB  |
| 12/ 2015   | 62     | Male   | IST                                 | -    | Yes      | LLL                             | IV   | -                          | < 80                                     | -            | Blood                         | 4.0  | 39  | slo, speB, speC, smeZ, SSA ssa |

Abbreviations: STSS, streptococcal toxic shock syndrome; ST, sequence type; IST, immunosuppressive therapy; Smoker, heavy smoker; COPD, chronic obstructive pulmonary disease; AHT, arterial hypertension; RF, renal failure; BS, bronchial secretion; DM, diabetes mellitus; HD, heart disease (excluding hypertension); ICU, intensive care unit; RUL, right upper lobe; RML, right middle lobe; RLL, right lower lobe; LLL, left lower lobe; Fine at admission

*+: Negative

doi:10.1371/journal.pone.0152640.t001
admission. Among lethal cases, there were 2 women aged 38 and 39 years without comorbidities or predisposing conditions.

In the multivariate logistic regression analysis, STSS was significantly associated with mortality ($p = .004$; odds ratio, 21.4; 95% CI, 2.7–170.7).

**Molecular Characterization of Isolates**

All isolates except one were available for molecular characterization (39/40). Eleven clones were identified (Fig 1). The most prevalent clone was emm1/ST28 (43.6%, 17/39), followed by emm3/ST15-315 (15.4%, 6/39), and emm6/ST382 (12.8%, 5/39). emm3/ST15 and emm3/ST315 isolates belong to the same clonal complex (http://www.phyloviz.net/goeburst/) and in this article were considered as the same clone. A sudden increase in case number was observed in cycles of 3–4 years, coinciding with the highest emm1/ST28 pneumonia cases (Fig 1).

The emm1/ST28 clone was implicated in 62.5% (5/8) of fatal outcomes, in 73.3% (11/15) of patients with multilobar pneumonia and in 60% (6/10) of patients who developed STSS (Table 1). The clones emm1/ST28 and emm3/ST15-ST315 were detected when seasonal influenza was above the epidemic threshold in 58.8% (10/17) and 66.7% (4/6) of times, respectively (Table 1).
Antimicrobial Susceptibility

All isolates were susceptible to penicillin (MIC < 0.06 mg/L), and clindamycin (MIC < 0.25mg/L). Only 1 isolate, an emm12/ST36 strain, showed resistance to macrolides; it harbored the mef gene and expressed the M phenotype of resistance (erythromycin MIC = 1 mg/L). Five isolates (12.5%) showed low-level levofloxacin resistance (three isolates MIC = 2 mg/L and two MIC = 4 mg/L), and all were characterized as emm6/ST382 (emm6.0 n = 4 and emm6.4 n = 1), and harbored the Ser79/Ala mutation in the parC gene, but no mutation was detected associated with fluoroquinolone resistance in the gyrA gene.

Exotoxins and Superantigen Profile

The streptococcal cysteine protease (speB) and the cytolytic toxin streptolysin O (slo) were present in all isolates. Overall, the most predominant superantigens genes among pneumonia isolates were speA (51.3%), smeZ (51.3%), speC (33.3%), and ssa (23.1%). A conservative superantigen profile was detected when the analysis was performed by clone. Isolates belonging to the emm1/ST28 clone harbored the smeZ (100%) and speA (82.4%). All emm3/ST15-315 isolates harbored the speA and ssa genes, and all emm6/ST382, emm75/ST150 and emm4/ST39 the speC gene (Table 1).

Discussion

In the 21st century, S. pyogenes pneumonia has been infrequently reported in detail. Since 2000, only 1 large series has been published describing the clinical presentation, prognosis and characteristics of the isolates [7]. Other publications have reported pneumonia as the clinical manifestation comprising the 7% to 11% of invasive S. pyogenes disease [6,16,17], but did not include specific details of these pneumonic episodes. The former articles, 1 outbreak in a military population [18], and some case reports [9–11], constitute the bulk of current information on this clinical entity. Therefore, is not surprising that S. pyogenes is not listed among CAP etiologies [19], or is only mentioned as a sporadic bacterial complication of influenza infection [4]. The incidence of most causes of CAP is not well defined. Apart from S. pneumoniae and Legionella pneumophila, Mycoplasma pneumoniae and Chlamydia pneumoniae are among persistently listed CAP etiologies [4,19]. The pneumonias caused by the latter two bacteria have a relative low fatality rate, and the incidence of pneumonia in adults is not too far from that obtained for S. pyogenes in the present series. In adult and children patients with CAP requiring hospitalization in U.S., Jain et al. found a similar presence of C. pneumoniae as S. pyogenes although a higher prevalence of M. pneumoniae [20,21]. Even so, some of these diagnoses were not specific enough as C. pneumoniae and M. pneumoniae were detected in nasopharyngeal or oropharyngeal swab by means of PCR assay. M. pneumoniae was found to be carried in the upper respiratory tract of a relatively high percentage of healthy, asymptomatic patients [22].

Annual average incidence of S. pyogenes pneumonia was of 1.14 episodes per 100,000 inhabitants (range 0.29–2.29). We assume it represents the minimum incidence as the study was a laboratory based surveillance study and some S. pyogenes pneumonia cases likely were not included in the study. The main finding in the present series was that S. pyogenes pneumonia was a severe clinical entity with a continuous presence in the community. Most cases occurred in winter and early spring (December to April), as observed in other series [7,8], and mainly affected males, especially elderly or adults with comorbidities. The only source of S. pyogenes infections are human beings and the most frequent focus of infection is the oropharynx. The pathogen can be introduced into the lungs through haematogenous spread or inhalation. The development of pneumonia in some individuals and not in others may depend on both host defenses and the virulence of the microorganism. Among the 40 cases, most patients (26/40
65%) were adults with comorbidities or other important risk factors, although remarkably there were 13 previously healthy people. Six of these healthy people developed severe symptoms (Fine IV or V) and two died.

Among the known risk factors facilitating aspiration of oropharyngeal secretions (decreased consciousness, neurological disorders) surveyed in the study, alcoholism or neurological disorders were evidenced in only 4 patients. Increased age is another risk factor that not only facilitates aspiration of oropharyngeal secretions, but is also associated with a weakened immune response and the presence of more comorbidities. In the present series, half of the patients (n = 20) were older than 60 years. The comorbidities most frequently encountered (hypertension, chronic obstructive pulmonary disease, diabetes mellitus, heart disease, and renal failure) coincided with those commonly found in patients with pneumonia, independently of the causal pathogen [7,23,24]. Apart from mortality, a number of features evidenced the severity of S. pyogenes pneumonia episodes: in more than half of the patients, the pneumonia coursed as an invasive infection, in 18 (45%) patients more than 1 lobe or cavitation was involved, and Fine severity index score placed more than 65% of patients in the intermediate to high risk group.

The 30-day death rate was remarkably high (20%), which elevated to 33.3% among invasive cases and to 30.8% in patients older than 64 years. The fatality rate associated to invasive pneumonia was higher than that associated to other invasive S. pyogenes infections [6,7,16]. Mortality rates higher than 30% have been reported by other authors in pneumonic patients with S. pyogenes invasive infections [7,8]. In the present series half of the patients with a fatal outcome showed rapid onset, dying in less than 24 hours after admission despite the implementation of aggressive supportive care measures and appropriate antibiotic therapy, coinciding with that observed in reports of fulminant S. pyogenes pneumonia [8,9].

The 20% of patients presented with mixed infections, 4 of them (10%) with influenza virus. Most CAP occur in the cold months, coinciding with the circulation of respiratory viruses. The relationship between influenza and S. pyogenes pneumonia in the present series was lower than usually reported [8, 25–27]. In the present series only 4 influenza coinfection episodes were confirmed and 1 suspected; and, although 19 pneumonias occurred during periods with high circulation of influenza virus, the remaining 21 episodes occurred outside these periods. The single episode of coinfection with influenza A H1N1pdm09 was detected in 2014, and surprisingly during the course of the main influenza pandemic of 2009, only one S. pyogenes pneumonia case was detected but it was not related with influenza virus. Co-infection with influenza B virus was detected in an elderly woman who died, highlighting the potential morbidity and mortality associated with influenza B virus in the context of concurrent influenza infection [27,28].

All but 3 pneumonic cases were community acquired. There have been reports of clusters of S. pyogenes pneumonia within the same family [29]. However, no clustering with any relationship among episodes was observed in the present study. We found that the same clone (emn1/ST28) caused an increase of pneumonic episodes in 2012 but no relationship between these patients could be established. This emn1/ST28 clone was the predominant (43.6%) one, followed by emn3/ST15-315 (15.4%) and emn6/ST382 (12.8%) clones. These emn types were also predominant in the series of Muller et al [7]. In 1981–1997, Barnham et al. found that 9 out 17 analyzed pneumonia episodes were caused by an emn1 isolate [8], and the most recently detected S. pyogenes pneumonia outbreak among Marine Corps personnel was due to an emn3/ST15 strain [18].

The increase of emn1/ST28 pneumonia cases each 3–4 years, was perhaps the consequence of some kind of herd immunity after an initial spread of this clone among a susceptible population, although the reason of the dynamics of circulation of clones is unclear.
Although the *emm1*/ST28 clone in the present series was not associated with death with statistical significance, it was involved in 62.5% of fatal outcomes, including 2 young adults without predisposing factors. Similarly, Santagati et al recently reported 3 cases of fulminant hemorrhagic pneumonia associated with *emm1*/ST28 strains in previously healthy patients [9]. In the present series, this clone was also related to 11 out of 15 episodes with multilobar pneumonia and in 3 of 4 episodes with cavitary lesions. The virulent potential of *emm1* isolates is well documented worldwide, with a coincident resurgence of severe invasive infections since the late 1980s [30]. Clinical and epidemiological data analysis, whole-genome sequencing analysis of large bacterial collections, and infection models in nonhuman primates have demonstrated that *emm1* strains recovered after 1988 are more virulent than those before 1988 due to acquisition of new genetic material [31].

As previously observed, a conservative superantigen profile by clone was frequently found [16]. For instance, almost all *emm1*/ST28 harbored the *speA* and *smeZ* superantigen genes. Overall, *speA* (51.3%), *smeZ* (51.3%) and *speC* (33.3%) were the most frequent superantigens genes found among pneumonia isolates.

Fortunately, all isolates were susceptible to clindamycin, which comprises a key antimicrobial for the treatment of severe *S. pyogenes* infections because it halts exotoxin production. Nonetheless, we detected a worryingly high rate of low level resistance to fluoroquinolones (12.8%) among strains associated with pneumonia, due to the involvement of isolates characterized as *emm6*/ST382, a clone which intrinsically harbors a mutation in the *parC* gene [32].

Although the representativeness of the study is limited to a specific geographic area, our findings suggest that today, as in the pre-antibiotic era, *S. pyogenes* pneumonia remains a very serious clinical entity, especially when it is associated with *emm1* strains. *S. pyogenes* pneumonia is more common than is generally supposed and is often unrelated to influenza infection. Although it affects mainly debilitated people, it can be rapidly fatal even in previously healthy individuals.

**Author Contributions**

Conceived and designed the experiments: EPT MM. Performed the experiments: ET DV MM. Analyzed the data: ET MM DV EPT. Contributed reagents/materials/analysis tools: DV. Wrote the paper: ET EPT MM.

**References**

1. Welch CC, Tombridge TL, Baker WJ, Kinney RJ. Beta hemolytic streptococcal pneumonia: report of an outbreak in a military population. Am J Med Sci. 1961; 242:157–65. PMID: 13784176
2. Basiliere JL, Bistrong HW, Spence WF. Streptococcal pneumonia. Recent outbreaks in military recruit populations. Am J Med. 1968; 44:580–89. PMID: 5642716
3. Ordman D. Pneumonia in the native mine labourers of northern Rhodesia copperfields with an account of an experiment in pneumonia prophylaxis by means of a vaccine at the Roan Antelope Mine. Publ S Afr Inst Med Res. 1935; 7(37):1–124.
4. Musher DM, Thorner AR. Community-acquired pneumonia. N Engl J Med. 2014; 371(17):1619–28. doi: 10.1056/NEJMra1312885 PMID: 25337751
5. Molina C, Walker DH. The pathology of community-acquired pneumonia. In: Marrie TJ editor. Community-Acquired pneumonia. New York: Kluwer Academic/Plenum Publishers; 2001.p. 101–129.
6. Stockmann C, Ampofo K, Hersh AL, Blaschke AJ, Kendall BA, Korgenski K, et al. Evolving epidemiologic characteristics of invasive group a streptococcal disease in Utah, 2002–2010. Clin Infect Dis. 2012; 55:479–87. doi: 10.1093/cid/cis422 PMID: 22534148
7. Muller MP, Low DE, Green KA, Simor AE, Loeb M, Gregson D et al. Clinical and epidemiologic features of group A streptococcal pneumonia in Ontario, Canada. Arch Intern Med. 2003; 163:467–72. PMID: 12586207

PLOS ONE | DOI:10.1371/journal.pone.0152640 March 30, 2016
8. Barnham M, Weightman N, Anderson A, Pagan F, Chapman S. Review of 17 cases of pneumonia caused by Streptococcus pyogenes. Eur J Clin Microbiol Infect Dis. 1999; 18:506–9. PMID: 10482030

9. Santagati M, Spanu T, Scillato M, Santangelo R, Cavallaro F, Arena V et al. Rapidly fatal hemorrhagic pneumonia and group a streptococcus serotype m1. Emerg Infect Dis. 2013; 20:98–101.

10. Siegel MD, Kimmel R. A 48-year-old woman with pneumonia, shock, and a rash. Chest. 2006; 129(6):1724–7. PMID: 16778296

11. Cengiz AB, Kanra G, Çağlar M, Kara A, Güçer S, Ince T. Fatal necrotizing pneumonia caused by group A streptococcus. J Paediatr Child Health. 2004; 40:69–71. PMID: 14718011

12. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997; 336:243–50. PMID: 8995086

13. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Fifth Informational Supplement. CLSI document M100-S25. CLSI, Wayne, PA, USA, 2015.

14. Pérez-Trallero E, Montes M, Orden B, Tamayo E, García-Arenzana JM, Marimón JM. Phenotypic and genotypic characterisation of Streptococcus pyogenes isolates displaying the MLSB phenotype of macrolide resistance in Spain, 1999 to 2005. Antimicrob Agents Chemother. 2007; 51:1228–33. PMID: 17242142

15. Yan SS, Fox ML, Holland SM, Stock F, Gill VJ, Fedorko DP. Resistance to multiple fluoroquinolones in a clinical isolate of Streptococcus pyogenes: identification of gyrA and parC and specification of point mutations associated with resistance. Antimicrob Agents Chemother. 2000; 44:3196–98. PMID: 11036052

16. Montes M, Ardanuy C, Tamayo E, Doménech A, Liñares J, Pérez-Trallero E. Epidemiological and molecular analysis of Streptococcus pyogenes isolates causing invasive disease in Spain (1998–2009): comparison with non-invasive isolates. Eur J Clin Microbiol Infect Dis. 2011; 30:1295–302. doi: 10.1007/s10096-011-1226-x PMID: 21491178

17. Olafsdottir LB, Erlendsdottir H, Melo-Cristino J, Weinberger DM, Ramirez M, Kristinsson KG, Gottfredsson M. Invasive infections due to Streptococcus pyogenes: seasonal variation of severity and clinical characteristics, Iceland, 1975 to 2012. Euro Surveill. 2014; 19:15–4.

18. Crum NF, Russell KL, Kaplan EL, Wallace MR, Wu J, Ashani P, et al. Pneumonia outbreak associated with group A Streptococcus species at a military training facility. Clin Infect Dis. 2005; 40:511–18. PMID: 15712072

19. Blasi F, Tarsia P, Cosentini R. Etiology and Investigation. In: Mandell L, Woodhead M, Ewig S, Torres A editors. Respiratory Infections. New York: Oxford University Press Inc.; 2006.p. 337–51.

20. Jain S, Self WH, Wunderink RG, Fakhran S, Balk R, Bramley AM, et al. Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults. N Engl J Med. 2015; 373:415–27. doi: 10.1056/NEJMoa1405870 PMID: 25714161

21. Jain S, Williams DJ, Arnold SR, Ampofo K, Bramley AM, Reed C, et al. Community-acquired pneumonia requiring hospitalization among U.S. children. N Engl J Med. 2015; 372(9):835–45 doi: 10.1056/NEJMoa1405870 PMID: 25714161

22. Spuesens EB, Fraaij PL, Visser EG, Hoogenboezem T, Hop WC, van Adrichem LN, et al. Carriage of Mycoplasma pneumoniae in the upper respiratory tract of symptomatic and asymptomatic children: an observational study. PLoS Med. 2013; 10: e1001444. doi: 10.1371/journal.pmed.1001444 PMID: 23690754

23. Santos JW, Nascimento DZ, Guerra VA, Rigo Vda S, Michel GT, Dalcin TC. Community-acquired staphylococcal pneumonia. J Bras Pneumol. 2008; 34(9):683–9. PMID: 18982205

24. Schreiber MP, Chan CM, Shorr AF. Bacteremia in Staphylococcus aureus pneumonia: outcomes and epidemiology. J Crit Care. 2011; 26:395–401. doi: 10.1016/j.jcc.2010.09.002 PMID: 21036521

25. Chertow DS, Memoli MJ. Bacterial coinfection in influenza: a grand rounds review. JAMA. 2013; 309(3):275–82. doi: 10.1001/jama.2012.194139 PMID: 23321766

26. Jean C, Louie JK, Glaser CA, Harriman K, Hacker JK, Aranki F et al. Invasive group A streptococcal infection concurrent with 2009 H1N1 influenza. Clin Infect Dis. 2010; 50:59–62.

27. Scabber J, Saeed S, Ihekweazu C, Efstratiou A, McCarthy N, O’Moore E. Group A streptococcal infections during the seasonal influenza outbreak 2010/11 in South East England. Euro Surveill. 2011; 16(5):pii = 19780.

28. Parola P, Colson P, Dubourg G, Million M, Charrel R, Minodier P et al. Letter to the editor. Group A streptococcal infections during the seasonal influenza outbreak 2010/11 in South East England. Euro Surveill. 2011; 16(11):pii = 19816.
29. Roy S, Kaplan EL, Rodriguez B, Schreiber JR, Salata RA, Palavecino E et al. A family cluster of five cases of group A streptococcal pneumonia. Pediatrics. 2003; 112(1 Pt 1):e61–65. PMID: 12837907

30. Davies HD, McGeer A, Schwartz B, Green K, Cann D, Simor AE et al. Invasive group A streptococcal infections in Ontario, Canada. Ontario Group A Streptococcal Study Group. N Engl J Med. 1996; 335:547–554. PMID: 8684408

31. Nasser W, Beres SB, Olsen RJ, Dean MA, Rice KA, Long SW et al. Evolutionary pathway to increased virulence and epidemic group A Streptococcus disease derived from 3,615 genome sequences. Proc Natl Acad Sci U S A. 2014; 111:1768–76.

32. Montes M, Tamayo E, Orden B, Larruskain J, Perez-Trallero E. Prevalence and clonal characterisation of *Streptococcus pyogenes* clinical isolates with reduced fluoroquinolone susceptibility in Spain. Antimicrob Agents Chemother. 2010; 54:93–97. doi:10.1128/AAC.00780-09 PMID: 19805559